Kissei Pharmaceutical Co., Ltd.

Makio Kitazawa

Kosuke Okazaki

Ken Kikuchi

Tetsuro Tamai

Nobuyuki Tanaka

Hideyuki Muranaka

Masuo Akahane

Hiroaki Kobayashi

Michihiro Kobayashi

Masaru Saito

Masaaki Ban

Yasushi Nakano

Atsushi Tsubaki

Kazuaki Sato

Norihiko Kikuchi

Hiroshi Miyata

Yukiyoshi Ajisawa

Tetsuya Nakamura

Hiroaki Shiohara

Ryoji Yamamoto

Toshiaki Yamaguchi

Tomonaga Ozawa

Yasuo Takehana

Ryoichi Yamagishi

Toshikazu Yazaki

Motoyasu Ozawa

Tsutomu Tsukamoto

The present invention provides a compound represented by general formula (I): or pharmaceutically acceptable salts thereof, wherein W is O, S(O), CHand the like; Ris halogen, lower alkyl, halo-lower alkyl, CN and the like; Ris hydrogen and the like; Ris hydrogen, halogen, alkyl, halo-lower alkyl, substituted alkyl, aryl, aralkyl, alkoxy, substituted alkoxy, alkanoyl, aroyl, &#x2014;CONR(R), &#x2014;S(O)R, &#x2014;SONR(R) and the like; Ris hydrogen, halogen, alkyl, substituted alkyl and the like; A is &#x2014;N(R)CO&#x2014;A&#x2014;CORand the like; pharmaceutical compositions containing them and their uses, which have a high affinity to human thyroid hormone receptors, in particular human thyroid hormone receptor &#x3b2;.

Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof

The present invention relates to indole derivatives represented by the general formula:

Indole derivatives and medicinal compositions containing the same

The present invention relates to an agent for the prevention or treatment of diseases associated with excessive proliferation of retinal pigment epithelial cells such as proliferative vitreoretinopathy comprising as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:

Preventives or remedies for diseases affecting excessive proliferation of retinal pigment epithelial cells

3,4-disubstituted phenylethanolaminotetralincarboxylic acid derivatives

3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives

Phenylethanolaminotetralincarboxamide derivatives

Indoline compounds represented by the formula: ##STR1## wherein R represents a saturated or unsaturated aliphatic acyl group which may have one or more halogen atoms, a hydroxy group, a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, a cycloalkyl group or an aryl group as substituents; a hydroxyalkyl group; an aliphatic acyloxyalkyl group; a lower alkyl group having a lower alkoxy group, a carboxy group, a lower alkoxycarbonyl group, an aryl substituted lower alkoxycarbonyl group, a carbamoyl group, a mono- or dialkyl substituted carbamoyl group or a cyano group as substituents; an aromatic acyl group which may have one or more halogen atoms as substituents; a furoyl group or a pyridylcarbonyl group; R.sup.1 represents a lower alkyl group which may have one or more halogen atoms or an aryl group as substituents; and pharmaceutically acceptable salts thereof, exhibit a selective suppressive action on urethral contractions, and thus are useful as therapeutic agents for the treatment of dysuria with less hypotension including postural hypotension.

1,5,7-trisubstituted indoline compounds and salts thereof

The present invention provides a novel class of naphthylsulfonylalkanoic acid compounds such as a structure corrresponding to the formula: ##STR1## or a pharmaceutically acceptable salt thereof. A present invention naphthylsulfonylalkanoic acid compound is useful for prevention or treatment of irritable bowel syndrome, biliary dyskinesia and acute pancreatitis.

Naphthysulfonylalkanoic acid compounds and pharmaceutical compositions

The present invention provides a novel class of phenylsulfonylalkanoic acid compounds such as a structure corresponding to the formula: ##STR1## or a pharmaceutically acceptable salt thereof. A present invention phenylsulfonylalkanoic acid compound is useful for prevention or treatment of irritable bowel syndrome, biliary dyskinesia and acute pancreatitis.

Phenylsulfonylalkanoic acid compounds and pharmaceuticals thereof

This invention provides novel isatin compounds which are useful as therapeutic agents. The invention isatin compounds and the pharmaceutically acceptable salts thereof exhibit anti-ulcer activities which are applicable for propylaxis and treatment of ulcer diseases in the digestive tract of animals.

Isatin compositions having anti-ulcer activities

Growing community of inventors

Matsumoto, Japan

Makio Kitazawa